• Sitagliptin Phosphate Monohydrate: Protocols and Troubleshoo

  2026-05-20

  Sitagliptin phosphate monohydrate empowers metabolic researchers with precision DPP-4 inhibition and reproducible incretin hormone modulation. This guide details workflow enhancements, protocol parameters, and troubleshooting strategies to maximize experimental success in type II diabetes and metabolic disease models.

• (+)-Bicuculline: Practical Guide to GABAA Receptor Antagonis

  2026-05-19

  (+)-Bicuculline provides a means to selectively antagonize GABAA receptors and dissect inhibitory neurotransmission in neuroscience research. This compound is not suitable for diagnostic or clinical use and demands precise handling for reproducible results.

• Trelagliptin Succinate in Diabetes Research: Applied Protoco

  2026-05-19

  Trelagliptin succinate (SYR-472 succinate) offers unique workflow advantages for diabetes mellitus research, enabling once-weekly, long-acting DPP-4 inhibition. This article distills validated experimental protocols, novel cognitive endpoints, and troubleshooting strategies to maximize data quality across metabolic and inflammation models.

• Single-Base 5hmC Mapping Illuminates Rice Drought Epigenetic

  2026-05-18

  This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, revealing how its genomic distribution and dynamic interplay with 5-methylcytosine (5mC) regulate gene expression during drought. The findings establish 5hmC as a context-dependent epigenetic mark, advancing research on plant stress adaptation and crop resilience.

• Enhanced mTOR Inhibitor Detection Using Drug-Sensitized Yeas

  2026-05-18

  Breen et al. introduce a yeast-based system with heightened sensitivity for identifying mechanistic target of rapamycin (mTOR) inhibitors, addressing the limitations of rapamycin and its analogs. This platform accelerates discovery of compounds with geroprotective and anti-cancer potential, and provides a robust negative control framework for non-TOR-targeted agents.

• A Drug-Sensitized Yeast Platform for mTOR Inhibitor Discover

  2026-05-17

  Breen et al. (2025) introduce a novel yeast-based assay system that dramatically increases sensitivity for detecting mTOR pathway inhibitors, facilitating rapid small-molecule screening. Their work clarifies that compounds like Canagliflozin do not cross-inhibit the mTOR pathway, guiding researchers toward more targeted, pathway-specific studies.

• Trelagliptin Succinate: Multidimensional Mechanisms in Diabe

  2026-05-16

  Explore the advanced biology of Trelagliptin succinate—a long-acting, selective DPP-4 inhibitor powering diabetes mellitus research and novel anti-inflammatory applications. Discover unique mechanistic insights and protocol strategies that set this compound apart.

• Anagliptin (SK-0403): DPP-4 Inhibition Meets Vascular Ion Ch

  2026-05-15

  Discover how Anagliptin (SK-0403) uniquely integrates DPP-4 inhibition with direct modulation of Kv channels and SERCA pumps, advancing research in diabetes and vascular physiology. This article uncovers the nuanced mechanisms and practical assay implications that set Anagliptin apart.

• Trelagliptin succinate (SKU A3889): Optimizing Diabetes Rese

  2026-05-15

  Explore how 'Trelagliptin succinate' (SKU A3889) addresses real-world laboratory challenges in diabetes mellitus research. This evidence-based article guides researchers through protocol optimization, assay compatibility, and data interpretation, emphasizing reproducibility, reliability, and validated best practices with direct links to protocols and supplier resources.

• Trelagliptin Succinate Restores Chondrocyte Function via AMP

  2026-05-14

  The referenced study demonstrates that trelagliptin succinate, a selective DPP-4 inhibitor, significantly counteracts IL-1β-induced dysfunction in human chondrocytes by activating the AMPK/SOX-9 pathway. These findings introduce a novel anti-inflammatory mechanism for a compound primarily used in type 2 diabetes research, with implications for osteoarthritis and metabolic disease comorbidity studies.

• Anagliptin (SK-0403): Applied DPP-4 Inhibition in Vascular R

  2026-05-14

  Unlock the dual power of Anagliptin (SK-0403) for both metabolic and vascular research: its ability to induce vasorelaxation via Kv channel and SERCA pump activation offers unique insight beyond glycemic control. This guide delivers protocol detail, troubleshooting, and advanced workflow strategies grounded in recent experimental breakthroughs.

• Triptolide (PG490): Precision Tool for Cancer and Immunology

  2026-05-13

  Triptolide (PG490) delivers nanomolar-potency inhibition of key inflammatory and cancer signaling pathways, enabling robust, reproducible research in oncology and immunology. This guide synthesizes experimental workflows and troubleshooting strategies—leveraging APExBIO’s validated Triptolide—for researchers seeking superior data clarity in cell-based and in vivo disease models.

• Cyclic di-GMP: Protocols for Biofilm & Immune Modulation Res

  2026-05-13

  Cyclic di-GMP stands at the crossroads of bacterial persistence and immune signaling, unlocking new workflows in both biofilm biology and cancer immunotherapy studies. This article delivers stepwise protocols, troubleshooting insights, and actionable context from the latest research, equipping scientists to harness this potent intracellular second messenger for advanced applications.

• TaqI Restriction Endonuclease: Fast, Reliable DNA Digestion

  2026-05-12

  TaqI Restriction Endonuclease (SKU K3053) provides rapid, sequence-specific DNA cleavage for applications requiring quick turnaround, such as cloning, analysis of plasmid or PCR products, and genomic DNA manipulation. It is not intended for diagnostic or medical use and should only be applied in research workflows where fast, efficient sticky end generation at the 5'…TCGA…3' site is required.

• Canagliflozin (hemihydrate): Precision for Glucose Metabolis

  2026-05-12

  This scenario-driven article equips biomedical researchers and lab technicians with practical, evidence-based strategies for using Canagliflozin (hemihydrate) (SKU C6434) in cell viability, proliferation, and cytotoxicity assays targeting glucose metabolism pathways. We address real laboratory challenges—ranging from assay specificity to product reliability—drawing on recent literature and validated best practices to ensure reproducibility and translational value.

16468 records 1/1098 page Next 12345 下5页 Last page